Novel Therapies and Stem Cell Transplant for Multiple Myeloma
Dr. Robert Orlowski, head of the myeloma section at MD Anderson Cancer Center, details a number of updates from the 2011 American Society of Hematology meeting. He explains data presented regarding newer drugs carfilzomib and bortezomib and a range of studies looking at consolidation and maintenance therapy following a stem cell transplant. He also talks about the expansion of newer tests to detect Minimal Residual Disease or MRD.
Experts & Guests
Robert Orlowski, M.D., Ph.D.
Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, MD Anderson Cancer CenterDr. Robert Z. Orlowski is Associate Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the... more >